Tokyo, Japan, May, 16 2012. - Sorin Group, (Reuters Code: SORN.MI), a global medical device company and a leader in the treatment of cardiovascular diseases, announces that it received authorization from the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) to market its MEMO 3D ...+
In the Spotlight
News
-
Primary objective of the prospective, non randomized trial is to demonstrate the safety and effectiveness of the PERCEVAL S sutureless valve in ...+
-
Mitroflow, the bioprosthesis that features proven clinical results1, 2, 3 Milan, Italy, December 4, 2012 – Sorin Group, ...+
-
Sorin’s Mitroflow Valsalva Conduit allows for safer device manipulation during assembly and implantation, thus limiting cardiac surgery ...+
-
European CE Mark approval for extended indications of the PERCEVALTM S Sutureless valve, expanding the market and paving the way for ...+
-
Tokyo, Japan, May, 16 2012. - Sorin Group, (Reuters Code: SORN.MI), a global medical device company and a leader in the treatment of ...+
-
Milan, Italy, 21 February, 2012 –Sorin Group, (Reuters Code: SORN.MI), a global medical company and a leader in the treatment of ...+
-
The Phospholipid Reduction Treatment (PRT) on the Mitroflow Aortic Pericardial Heart Valve is designed to mitigate calcification of the ...+
-
Discover the video "Nicole Sarim, A first-hand testimony of durability and performance", highlighting the quality and reliability of ...+
-
First North American implant of the Freedom Solo™ aortic valve, performed at Hopital Laval, Division of Cardiac Surgery in Quebec City, ...+
-
More than 100,000 Mitroflow® Aortic Pericardial Heart Valves Implanted Worldwide. Milan, Italy. February 21, 2011 – ...+